Статья

Regional Differences in Stage III Nonseminoma Germ Cell Tumor Patients Across SEER Registries

Cristina Cano GarciaCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Goethe University Frankfurt, Department of Urology, University Hospital Frankfurt, Frankfurt, Germany. Electronic address: [email protected]Francesco BarlettaCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, ItalyStefano TapperoCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, IRCCS Policlinico San Martino, Genova, Italy; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, ItalyMattia Luca PiccinelliCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, ItalyReha‐Baris IncesuCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, GermanySimone MorraCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples Federico II, Naples, ItalyLukas ScheipnerCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, Medical University of Graz, Graz, AustriaZhe TianCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, CanadaFred SaadCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, CanadaShahrokh F. ShariatDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern, Dallas, TX; Hourani Center of Applied Scientific Research, Al-Ahliyya Amman University, Amman, JordanSascha AhyaiDepartment of Urology, Medical University of Graz, Graz, AustriaNicola LongoDepartment of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples Federico II, Naples, ItalyDerya TilkiMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, TurkeyOttavio De CobelliDepartment of Urology, IEO European Institute of Oncology, IRCCS, Milan, ItalyCarlo TerroneDepartment of Urology, IRCCS Policlinico San Martino, Genova, Italy; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, ItalyAlberto BrigantiUnit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, ItalySéverine BanekGoethe University Frankfurt, Department of Urology, University Hospital Frankfurt, Frankfurt, GermanyLuis A. KluthGoethe University Frankfurt, Department of Urology, University Hospital Frankfurt, Frankfurt, GermanyFelix K.‐H. ChunGoethe University Frankfurt, Department of Urology, University Hospital Frankfurt, Frankfurt, GermanyPierre I. KarakiewiczCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada

2024en

ABI

Аннотация

PurposeWe investigated regional differences in patients with stage III non-seminoma germ cell tumor (NSGCT). Specifically, we investigated differences in baseline patient, tumor characteristics and treatment characteristics, as well as cancer-specific mortality (CSM) across different regions of the United States.MethodsUsing the Surveillance, Epidemiology, and End Results (SEER) database (2004-2018), patient (age, race/ethnicity), tumor (International Germ Cell Cancer Collaborative Group [IGCCCG] prognostic groups) and treatment (systemic therapy and retroperitoneal lymph dissection [RPLND] status) characteristics were tabulated for stage III NSGCT patients, according to 12 SEER registries representing different geographic regions. Multinomial regression models and multivariable Cox regression models testing for cancer-specific mortality (CSM) were used.ResultsIn 3,174 stage III NSGCT patients, registry-specific patient counts ranged from 51 (1.5%) to 1630 (51.3%). Differences across registries existed for age (12-31% for age 40+), race/ethnicity (5-73% for others than non-Hispanic whites), IGCCCG prognostic groups (24-43% vs. 14-24% vs. 3-20%, in respectively poor vs. intermediate vs. good prognosis), systemic therapy (87-96%) and RPLND status (12-35%). After adjustment, clinically meaningful inter-registry differences remained for systemic therapy (84-97%) and RPLND (11-32%). Unadjusted five-year CSM rates ranged from 7.1 to 23.3%. Finally in multivariable analyses addressing CSM, two registries exhibited more favorable outcomes than SEER registry of reference (SEER Registry 12): SEER Registry 4 (Hazard Ratio (HR): 0.36) and SEER Registry 9 (HR: 0.64; both p=0.004).ConclusionWe identified important regional differences in patient, tumor and treatment characteristics, as well as CSM which may be indicative of regional differences in quality of care or expertise in stage III NGSCT management.MicroAbstractOur study analyzed regional variations in patient demographics, tumor prognostics, and treatment outcomes among stage III non-seminoma germ cell tumor patients using the SEER database. It found significant differences in systemic therapy and retroperitoneal lymph dissection rates, as well as cancer-specific mortality across regions, suggesting potential disparities in care quality or expertise.

Перевод пока недоступен

Идентификаторы

DOI: 10.1016/j.clgc.2024.102161

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar